DENVER, CO, August 3, 2005, GlobeImmune, Inc., a biopharmaceutical company that discovers and manufactures immunotherapy products known as Tarmogens™ to treat cancer and infectious disease, today announced the appointment of Francis V. Chisari, M.D. to its Scientific Advisory Board. “We … Continue reading
DENVER, CO, July 26, 2005, GlobeImmune, Inc., a biopharmaceutical company that discovers, develops and manufactures immunotherapeutic products known as Tarmogens™ to treat cancer and infectious disease, today announced that it has initiated a Phase 1b study of GI-5005, a Tarmogen … Continue reading
DENVER, CO, January 17, 2005 – GlobeImmune and Mycologics announce today that they have signed a non-exclusive research license and option agreement under which Mycologics will pursue select antifungal products under the GlobeImmune Tarmogen Technology. The license agreement enables MycoLogics … Continue reading
Aurora, CO, January 5, 2005 GlobeImmune, Inc., a development-stage biopharmaceutical company, today announced the appointment of two management team members. “We are pleased that GlobeImmune has been able to fill these two key positions,” said Timothy C. Rodell, M.D., GlobeImmune’s … Continue reading
Aurora, CO, September 13, 2004. GlobeImmune, Inc. today announced the appointment of Dr. Paul Bunn to its Scientific Advisory Board. Dr. Bunn is the Grohne-Stapp Endowed Professor of Oncology Research and Director of the University of Colorado Cancer Center in … Continue reading
Aurora, CO, August 26, 2004. GlobeImmune, Inc., a development-stage biopharmaceutical company, today announced the appointment of five management team members including key hires at the director and department head level. “We are pleased that GlobeImmune has continued to attract the … Continue reading
AURORA, CO, May 25, 2004 – GlobeImmune, Inc. today announced that the Company’s Investigational New Drug (IND) application for the GI-4000 product series, filed with the U.S. Food & Drug Administration last month, has become effective after the initial 30-day … Continue reading
AURORA, CO, May 13, 2004 – GlobeImmune, Inc. today announced that Teresa Brentnall, MD, Edgar Engleman, MD, Edward Mocarski, PhD, Alan Venook, MD, and Bruce Walker, MD have been appointed to the company’s Scientific Advisory Board. “These outstanding professionals in … Continue reading
AURORA, Colorado, December 19, 2003 — GlobeImmune, Inc. today announced that Dr. Alex Franzusoff has been appointed Vice President of Research. Dr. Franzusoff, one of the Company’s three scientific founders, was most recently Associate Professor of Cellular and Developmental Biology … Continue reading
AURORA, Colo., June 18, 2003 — GlobeImmune, Inc. today announced the closing of a Series A Preferred venture financing round. The round provides for up to a total of $8 million in two tranches, with closure of the second tranche … Continue reading